Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 128Head & Neck 56Other hematologic neoplasm 14Plasma cell 10Lymphoid 10Gastrointestinal 6Sarcoma 4Genitourinary 3Classical hematology 3Breast 3Thoracic 2Myeloid 2CNS 2Endocrine 1

Conditions

Neuroendocrine Tumors 531Multiple Endocrine Neoplasia Type 1 187Pituitary Neoplasms 186Thyroid Cancer, Papillary 178Pheochromocytoma 152Carcinoma, Neuroendocrine 140Thyroid Neoplasms 130Neoplasms 107Carcinoid Tumor 99Paraganglioma 98Adrenocortical Carcinoma 92Thyroid Carcinoma, Anaplastic 82Pancreatic Neoplasms 69Neoplasm Metastasis 67Insulinoma 61Adrenal Gland Neoplasms 61Gastro-enteropancreatic neuroendocrine tumor 58Carcinoma, Medullary 58Adenocarcinoma, Follicular 58Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 56Adenoma, Islet Cell 56Lung Neoplasms 50Sarcoma 49Colorectal Neoplasms 49Carcinoma, Renal Cell 49Melanoma 47Small Cell Lung Carcinoma 45Prostatic Neoplasms 44Head and Neck Neoplasms 43

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mucositis × Endocrine × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡